Published on 7 Mar 2024 on GuruFocus.com via Yahoo Finance

OrthoPediatrics Corp (KIDS) Reports Robust Revenue Growth and Improved Adjusted EBITDA in 2023

Full Year Revenue: OrthoPediatrics Corp (NASDAQ:KIDS) achieved a record $148.7 million in 2023, marking a 22% increase year-over-year.Adjusted EBITDA: The company reported a record full year adjusted EBITDA of $5.0 million in 2023, a significant rise from $0.2 million in 2022.Product Launches: OrthoPediatrics launched 8 new products in 2023, contributing to its comprehensive pediatric orthopedic offerings.Acquisition: The acquisition of Boston Orthotics & Prosthetics expanded OrthoPediatrics' Specialty Bracing Division.Net Loss: The company reported a net loss of $21.0 million for the full year 2023, compared to a net income of $1.3 million in the previous year.2024 Revenue Guidance: OrthoPediatrics reiterated its full year 2024 revenue guidance, expecting growth of 32% to 34% over 2023 revenue.

Warning! GuruFocus has detected 5 Warning Signs with KIDS.

On March 6, 2024, OrthoPediatrics Corp (NASDAQ:KIDS), a leader in the pediatric orthopedic market, announced its financial results for the fourth quarter and full year ended December 31, 2023. The company released its 8-K filing, detailing a year of substantial growth and strategic advancements. OrthoPediatrics Corp is dedicated to improving the lives of children with orthopedic conditions through its extensive product portfolio, which includes innovative solutions such as PediLoc, PediPlates, and the ACL Reconstruction System.